CYMEVENE 500mg price in UAE

Overview

Welcome to Dwaey, specifically on CYMEVENE 500mg Infusion/Powder for page.
This medicine contains an important and useful components, as it consists of Ganciclovir.
CYMEVENE 500mg is available in the market in concentration 500mg/Vial and in the form of Infusion/Powder for.

CHEPLAPHARM ARZNEIMITTEL GMBH is the producer of CYMEVENE 500mg and it is imported from GERMANY, The most popular alternatives of CYMEVENE 500mg are listed downward .

Mode Of Action

Ganciclovir is a synthetic guanine nucleoside analogue with activity against cytomegalovirus (CMV). It competitively inhibits the binding of deoxyguanosine triphosphate to DNA polymerase, thus inhibiting viral DNA synthesis.

Indication

CMV retinitis
Pneumonitis
Cytomegaloviral infections

Precaution

Renal impairment; preexisting cytopenias or history of cytopenic reactions to drugs; child; contraceptive precautions to be followed during and at least 90 days thereafter; care in administering only into veins with good blood flow. Avoid contact with the skin and eyes. Maintain adequate hydration during infusion. Monitor WBC and platelet counts regularly during treatment. Eye examinations should be conducted at least once every 4-6 wk during treatment for CMV retinitis. Lactation: excretion in milk unknown; use with caution

Side Effects

Opthalmic >10% Blurred vision (60%)
Eye irritation (20%) 1-10% Punctate keratitis (5%)
Conjunctival hyperemia (5%) Intravenous >10% Neutropenia w/ ANC <1000/cu.mm (25-50%)
Thrombocytopenia (20%) 1-10% Abnl LFTs
Anemia
Confusion
Headache
Nausea/vomiting
Neuropathy
Paresthesia
Pruritus
Retinal detachment
Rash
Sepsis
Weakness

Contra indication

Hypersensitivity; absolute neutrophil count <500 cells/mm3; platelet count <25,000/mm3; pregnancy, lactation. Not to be used as a bolus inj.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Increased risk of haematologic toxicity w/ zidovudine. May increase serum levels of didanosine. Increased serum concentration w/ probenecid and other drugs that inhibit renal tubular secretion and resorption. Use of IV ganciclovir w/ oral mycophenolate mofetil may result in increased plasma concentrations of both drugs due to competition for renal tubular secretion. Concomitant use w/ immunosuppressive agents (e.g. azathioprine, ciclosporin, corticosteroids) may result in excessive suppression of bone marrow or the immune system. Generalised seizure may occur when taken w/ imipenem and cilastatin. Concurrent use w/ drugs that inhibit replication of rapidly dividing cells (e.g. dapsone, pentamidine, pyrimethamine, flucytosine, cytotoxic antineoplastic agents, amphotericin B, co-trimoxazole, other nucleoside analogues) may result in additive toxicity.